RxDoctor Payments Data

Salman Saeed, MD

Neurology · Bartlett, TNNPI 1528051125

Payments from drug & device makers

$21,782in general payments, 2019–2025

Across 1,242 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • SK Life Science, Inc.$1K
  • EMD Serono, Inc.$1K
  • plus $13K from 51 others

What the payments were for

  • Speaking & faculty fees$440%
  • Food & beverage$21,62799%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis128$2,408
AbbVie(2 entities)148$1,649
Teva Pharmaceuticals USA, Inc.94$1,462
Biogen62$1,243
SK Life Science, Inc.56$1,176
EMD Serono, Inc.55$1,064
Lilly USA, LLC53$982
UCB, Inc.47$965
Neurocrine Biosciences, Inc.29$774
Lundbeck LLC38$736
Pfizer41$719
Argenx US, Inc.31$676
Amneal Pharmaceuticals LLC46$660
MDD US Operations, LLC39$568
Sunovion Pharmaceuticals Inc.37$556
Neurelis, Inc.30$546
Upsher-smith Laboratories LLC28$503
Amgen(2 entities)23$434
AstraZeneca(2 entities)22$418
Avanir Pharmaceuticals, Inc.20$383
Johnson & Johnson17$343
Banner Life Sciences, LLC15$314
Bristol Myers Squibb16$304
Biohaven Pharmaceuticals, Inc.21$260
Eisai Inc.14$241
Jazz Pharmaceuticals Inc.13$235
Supernus Pharmaceuticals, Inc.18$222
Genentech USA, Inc.15$215
Otsuka America Pharmaceutical, Inc.10$186
Acadia Pharmaceuticals Inc7$150
Harmony Biosciences LLC6$141
Catalyst Pharmaceuticals, Inc.6$139
Sumitomo Pharma America, Inc.6$128
Tanabe Pharma America, Inc.6$95
Sanofi4$89
Acorda Therapeutics, Inc4$83
ANI Pharmaceuticals, Inc.4$82
Vanda Pharmaceuticals Inc.4$79
Livanova USA, Inc.4$75
Mallinckrodt Enterprises LLC3$72
Axsome Therapeutics, Inc.2$59
E.r. Squibb & Sons, L.L.C.2$46
C2n Diagnostics, LLC2$41
Avion Pharmaceuticals2$40
Merz Pharmaceuticals, LLC1$21
Scilex Pharmaceuticals Inc.1$21
TG Therapeutics, Inc.1$21
Adamas Pharmaceuticals, Inc.1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Promius Pharma LLC1$17
GSK1$17
Biohaven Pharmaceutical Holding Company Ltd.1$16
Kyowa Kirin, Inc.1$16
GRT US Holding, Inc.1$15
CSL Behring1$14
Vertical Pharmaceuticals, LLC1$12
Corium, LLC2$12

How this compares

$21,782 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$337,223
Medicare patients
746
Services billed
2,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl18$881,341
Kesimpta PenOfatumumab14$201,547
VumerityDiroximel Fumarate12$120,106
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$96,957
Aimovig AutoinjectorErenumab-Aooe103$77,358
XcopriCenobamate61$75,015
Rufinamide12$62,617
Nurtec OdtRimegepant Sulfate33$49,547
BotoxOnabotulinumtoxina36$45,552
Emgality PenGalcanezumab-Gnlm54$38,256
ValtocoDiazepam13$33,989
NuedextaDextromethorphan Hbr/Quinidine18$30,841
AptiomEslicarbazepine Acetate20$26,809
UbrelvyUbrogepant20$23,720
Droxidopa19$22,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$719$146,50550 claims
BiogenVumerity$1,243$120,10612 claims
SK Life Science, Inc.Xcopri$1,176$75,01561 claims
AbbVieBotox, Ubrelvy$1,649$69,27256 claims
Neurelis, Inc.Valtoco$546$33,98913 claims
Avanir Pharmaceuticals, Inc.Nuedexta$383$30,84118 claims
Sunovion Pharmaceuticals Inc.Aptiom$556$26,80920 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$660$21,16539 claims
Upsher-smith Laboratories LLCTopiramate$503$2,639291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Bartlett

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →